BioSpace News Archive

Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low doses of GLP-1/GLP-2 receptor dual agonist dapiglutide

Kazia Therapeutics Limited received a letter on May 22, 2024 from Nasdaq notifying the Company that, while the Company has not regained compliance with the Minimum Bid Price Requirement, Nasdaq has determined that the Company is eligible for an additional 180 calendar day period, or until November 18, 2024, to regain compliance with the Minimum Bid Price Requirement.

Breaking research demonstrates that clinical labs should account for the self-reported race of pregnant individuals when screening for spina bifida and other open neural tube defects.

Harvard Bioscience, Inc. announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will be presenting to investors at the Jefferies Global Healthcare Conference at the Marriott Marquis in New York City on June 5, 2024.

Vaxart, Inc. announced that on May 17, 2024, the Compensation Committee of the Board of Directors granted inducement equity awards covering an aggregate of 22,500 shares of its common stock to one new non-executive employee to induce him to accept employment with Vaxart.

AbbVie announced that it has completed its acquisition of Landos Biopharma, Inc.

Tyra Biosciences, Inc., a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor biology, announced that company management will participate in the following investor conferences.

Azenta, Inc. announced that Company management will participate in the Jefferies Global Healthcare Conference in New York, NY, on Wednesday, June 5, 2024, which includes a presentation beginning at 11:00 am ET.

Owlet , Inc. (“Owlet” or the “Company”) (NYSE: OWLT), the pioneer of smart infant monitoring, announced today its participation in the 8th Annual Cowen Future of the Consumer Conference, being held in New York City on June 4-5, 2024.

Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR), announced today it received notice of a delisting determination (the “Staff Delisting Determination”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”).